1-nonacosanol | 6624-76-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-nonacosanol
• 英文别名: nonacosanol；nonacosan-1-ol；n-nonacosanol；Nonacosanol-(1)
• CAS: 6624-76-6
• 化学式: C₂₉H₆₀O
• 分子量: 424.795
• InChiKey: PKBSGDQYUYBUDY-UHFFFAOYSA-N

物化性质

• 熔点：
  84.5°C
• 沸点：
  470.73°C (rough estimate)
• 密度：
  0.8678 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  14.3
• 重原子数：
  30
• 可旋转键数：
  27
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-nonacosanol 以60%的产率得到
  参考文献：
  名称：

  DANILOV, L. L.;MALTSEV, S. D.;SHIBAEV, V. N., BIOORGAN. XIMIYA, 16,(1990) N, S. 1002-1003

  摘要：

  DOI：
• 作为产物：
  描述：

  二十九烷酸甲酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 1-nonacosanol
  参考文献：
  名称：

  Rao, S. Jagadishwar; Bhalerao, U. T.; Tilak, B. D., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1987, vol. 26, # 1-12, p. 208 - 211

  摘要：

  DOI：

文献信息

• [EN] CELLULAR SIGNALLING INHIBITORS, THEIR FORMULATIONS AND METHODS THEREOF<br/>[FR] INHIBITEURS DE SIGNALISATION CELLULAIRE, LEURS FORMULES ET LEURS PROCÉDÉS
  申请人：INVICTUS ONCOLOGY PVT LTD

  公开号：WO2017137958A1

  公开（公告）日：2017-08-17

  The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula (I), compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof.

  本公开涉及一般细胞信号传导抑制剂，涉及式(I)的化合物、包含该化合物的组合物和制剂、以及它们的方法、过程和使用。特别是，本公开提供了CSF-1R抑制剂，它们表现出对CSF/CSF1R信号通路的持续抑制，并且毒性降低。本公开还提供了超分子组合疗法，其中CSF-1R抑制剂与一个或多个化疗剂、激酶抑制剂和免疫调节剂结合，其中每个可选地与脂质偶联。本公开还提供了一种治疗癌症、过敏、系统性红斑狼疮、肾炎、慢性阻塞性肺病和异常巨噬细胞功能或其任何组合的方法。
• [EN] NOVEL INHIBITORS OF CELLULAR SIGNALLING<br/>[FR] NOUVEAUX INHIBITEURS DE SIGNALISATION CELLULAIRE
  申请人：INVICTUS ONCOLOGY PVT LTD

  公开号：WO2018146641A1

  公开（公告）日：2018-08-16

  The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula I, compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors of BLZ-945-lipids conjugates, GW2580-lipid conjugates and PLX-3397-lipid conjugates demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof.

  本公开涉及一般性地与化合物I的细胞信号抑制剂有关，包括包含相同的组合物和配方、方法、过程和用途。具体而言，本公开提供了BLZ-945-脂质共轭物、GW2580-脂质共轭物和PLX-3397-脂质共轭物的CSF-1R抑制剂，表现出对CSF/CSF1R信号通路的持续抑制并降低毒性。本公开还提供了超分子组合治疗方法，其中CSF-1R抑制剂与化疗药物、激酶抑制剂和免疫调节剂中的一个或多个结合，每种药物可选择性地与脂质共轭。本公开还提供了一种治疗癌症、过敏、系统性红斑狼疮、肾炎、慢性阻塞性肺病和异常巨噬细胞功能或其任何组合的方法。
• CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
  申请人：Bapat Abhijit S.

  公开号：US20140364595A1

  公开（公告）日：2014-12-11

  The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; or (iv) (AFA) m″ -X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.

  该发明提供了由至少一种抗真菌剂或抗菌剂与至少一种连接剂和/或载体偶联形成的基于共轭的抗真菌或抗菌前药。这些前药的公式为：(i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; 或 (iv) (AFA) m″ -X，其中：AFA是抗真菌剂或抗菌剂；L是载体；X是连接剂；m范围从1到10；n范围从2到10；m′为1到10；p为1到10；n′为1到10；q为1到10，前提是q'和n不同时为1；m″为1到10。该发明还提供了包含基于共轭的前药的纳米粒子。此外，该发明还提供了以纳米粒子形式的非共轭抗真菌和抗菌剂。
• [EN] ORTHO-TERPHENYLS FOR THE PREPARATION OF GRAPHENE NANORIBBONS<br/>[FR] ORTHO-TERPHENYLES POUR LA PREPARATION DE NANORUBANS DE GRAPHENE
  申请人：BASF SE

  公开号：WO2015173215A1

  公开（公告）日：2015-11-19

  The present invention concerns ortho-Terphenyls of general formula (I); wherein R1, R2, R3 and R4 are independently selected from the group consisting of H; CN; NO2; and saturated, unsaturated or aromatic C1-C40 hydrocarbon residues, which can be substituted 1 - to 5- fold with F, CI, OH, NH2, CN and/or NO2, and wherein one or more -CH2-groups can be replaced by -O-, -NH-, -S-, -C(=O)O-, -OC(=O)- and/or -C(=O)-; and X and Y are the same or different, and selected from the group consisting of F, CI, Br, I, and OTf (trifluoromethanesulfonate); and their use for the preparation of graphene nanoribbons as well as a process for the preparation of graphene nanoribbons from said ortho-Terphenyls.

  本发明涉及一般式(I)的邻二联苯；其中R1、R2、R3和R4分别选自H；CN；NO2；以及饱和、不饱和或芳香族C1-C40烃基，该烃基可用F、Cl、OH、NH2、CN和/或 取代1至5次，并且一个或多个-CH2基团可被-O-、-NH-、-S-、-C(=O)O-、-OC(=O)-和/或-C(=O)-取代；X和Y相同或不同，选自F、Cl、Br、I和OTf（三氟甲磺酸盐）；以及它们用于制备石墨烯纳米带，以及从所述邻二联苯制备石墨烯纳米带的方法。
• FLUORESCENT ANTICANCER PLATINUM DRUGS
  申请人：INVICTUS ONCOLOGY PVT. LTD.

  公开号：US20180312534A1

  公开（公告）日：2018-11-01

  The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to fluorescent platinum based compounds. The disclosure further relates to synthesis of said fluorescent platinum based compounds, nanoparticles and compositions comprising said fluorescent platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by the fluorescence changes between aforesaid platinum based compounds and corresponding free ligands, nanoparticles and compositions.

  本公开涉及纳米技术和癌症治疗领域。具体而言，本公开涉及荧光铂基化合物。该公开进一步涉及合成所述荧光铂基化合物、纳米颗粒和包含所述荧光铂基化合物/纳米颗粒的组合物。该公开还涉及通过上述铂基化合物与相应的游离配体、纳米颗粒和组合物之间的荧光变化来管理癌症的方法。